



Sara Koski

Counsel

sara.koski@dlapiper.com

Sara assists clients in a broad range of compliance matters including design and implementation of compliance programs, carrying out risk mappings, anti-corruption due diligence and internal investigations regarding both general anti-corruption regulations and in the life sciences sector.

Sara began her career with compliance & risk management and life sciences teams in the Paris office of a leading American law firm. She has developed an in-depth experience in relation to the investigation and prevention of corruption and related issues in France (in particular, "Sapin II" Law anti-corruption measures, French "Duty of Vigilance" Law, Registers of lobbyists and beneficial owners, etc.).

Her experience also covers compliance aspects in the life sciences sector (French "Anti-Gift Law" and "Sunshine Act", sector specific ethical guidance and rules adopted by SNITEM, LEEM MedTech Europe, EFPIA, etc.).

- White Collar and Corporate Crime
- Litigation, Arbitration and Investigations

- Life Sciences

- Assistance of a French based global group in the context of development of compliance processes to meet requirements under Sapin II law relating to anti-bribery and anti-corruption aspects and under a so-called Duty of vigilance law relating to corporate social responsibility, including development of risk assessment materials, design and roll-out of various compliance procedures for the group worldwide (including: code of conduct, whistleblowing hotline, etc.)
- Assistance of an international group with the design and implementation of a global compliance program for all entities of the group present on 5 continents: global risk assessment, subsequent design and roll-out of compliance procedures (including an anti-corruption policy, third party screening mechanisms, conflict of interest policy)
- Assistance of the French subsidiary of a global group with the design of its governance and compliance functions (compliance officer's role, duties, reporting lines, hierarchical position, and resources)
- Assistance of a French based global company in the context of a multi-jurisdictional survey relating to EU beneficial owner rules and their transposition in the national laws

Publications

COVID-19 Litigation and Regulatory Q&A: France

20 May 2020

What is the status of the major courts or arbitral institutions in France? Are they operating as usual, and if not what alternative procedures are in place? Am I required to attend a hearing in person at this time in France? Given there are significant local movement restrictions, are there any new or alternate procedures in place?

- *France - Whistleblowing Laws in Europe: An international guide*, DLA Piper Insights, June 2021
- *Publication des nouvelles recommandations de l'Agence française anticorruption*, DLA Piper Insights, January 2021
- *COVID-19 Litigation and Regulatory Q&A: France*, DLA Piper Insights, May 2020
- Contribution to DLA Piper Coronavirus Resource Center regarding life science regulations, 2020
- *France - Global bribery offenses guide*, DLA Piper Insights, December 2019

Events

- Co-speaker with Theobald Naud at HEC International Contracts class regarding compliance risk in third party relations on 7 February, 2020